Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news

    pharma-news - Page 38

    German drug assessment body not convinced by Bayers cancer drug Vitrakvi

    German drug assessment body not convinced by Bayer's cancer drug Vitrakvi

    Medical Dialogues Bureau19 Jan 2020 9:30 AM IST
    Frankfurt: Germany's drug assessment body said that data provided by Bayer on its precision cancer drug Vitrakvi did not provide clear enough evidence...
    Piramal Divests its Healthcare analytics Business for 950 Million USD

    Piramal Divests its Healthcare analytics Business for 950 Million USD

    Medical Dialogues Bureau18 Jan 2020 3:30 PM IST
    India: Piramal Enterprises Limited has announced that PEL DRG Dutch HoldCo BV, a 100% subsidiary of PEL and the holding company for Decision Resources...
    Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

    Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

    Medical Dialogues Bureau18 Jan 2020 12:17 PM IST
    New York: A Pennsylvania court on Friday slashed a USD 8 billion ruling against US pharmaceutical giant Johnson & Johnson, imposed by a jury...
    Novo Nordisks Ozempic® gets USFDA for CV risk reduction in people with type 2 diabetes and established CVD

    Novo Nordisk's Ozempic® gets USFDA for CV risk reduction in people with type 2 diabetes and established CVD

    Medical Dialogues Bureau18 Jan 2020 10:36 AM IST
    Denmark: Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved a label expansion based on a supplemental New...
    Wockhardt gets DCGI nod for 2 new antibiotics

    Wockhardt gets DCGI nod for 2 new antibiotics

    Medical Dialogues Bureau17 Jan 2020 1:57 PM IST
    'DCGI has approved Wockhardts 2 new antibiotics, EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure Infections including...
    Group B Streptococcus: Hilleman Labs announces to make affordable vaccine

    Group B Streptococcus: Hilleman Labs announces to make affordable vaccine

    Medical Dialogues Bureau17 Jan 2020 1:27 PM IST
    New Delhi:: In a bid to strengthen its vaccine portfolio and expand into areas of unmet need, Hilleman Laboratories, a global research and development...
    Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO

    Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO

    Medical Dialogues Bureau17 Jan 2020 12:45 PM IST
    San Francisco: Eli Lilly and Co aim to announce roughly one $1 billion (765 million pounds) to $5 billion (3.8 billion pounds) deal every quarter in...
    Govt may impose anti-dumping duty on pharma chemical from China, Saudi Arabia

    Govt may impose anti-dumping duty on pharma chemical from China, Saudi Arabia

    Medical Dialogues Bureau17 Jan 2020 12:00 PM IST
    New Delhi: The government may impose anti-dumping duty on a chemical used in pharma and pesticide industries from China and Saudi Arabia with a view...
    Sun Pharma, Rockwell Medical ink licensing pact for Triferic in India

    Sun Pharma, Rockwell Medical ink licensing pact for Triferic in India

    MD bureau16 Jan 2020 10:30 AM IST
    As per the terms of the agreement, Sun Pharma will be the exclusive development and commercialisation partner for Triferic during the term of the...
    Drug Alert: CDSCO declares 49 drug samples as Not of Standard Quality; Details

    Drug Alert: CDSCO declares 49 drug samples as Not of Standard Quality; Details

    Farhat Nasim14 Jan 2020 2:32 PM IST
    New Delhi: In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) recently flagged 49...
    Lupin Tarapur facility cautioned by USFDA post inspection

    Lupin Tarapur facility cautioned by USFDA post inspection

    Farhat Nasim14 Jan 2020 1:11 PM IST
    "The company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between...
    Alembic Pharma gets USFDA nod for depression drug Vilazodone Hydrochloride tablets

    Alembic Pharma gets USFDA nod for depression drug Vilazodone Hydrochloride tablets

    Farhat Nasim14 Jan 2020 12:52 PM IST
    "The approved ANDA (Vilazodone Hydrochloride tablets) is therapeutically equivalent to the reference listed drug product (RLD), Viibryd tablets, 10...
    PrevNext

    Popular Stories

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Lupin gets USFDA EIR for Nagpur Facility

    Lupin gets USFDA EIR for Nagpur Facility

    GSK , Vir Biotechnology enter collaboration to find coronavirus solutions

    GSK , Vir Biotechnology enter collaboration to find coronavirus solutions

    Top priority on Delivery of Medicines through Speed Post: Minister

    Top priority on Delivery of Medicines through Speed Post: Minister

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok